0
Sickle Cell Care Expansion Act of 2023
2/16/2024, 9:08 PM
Summary of Bill S 1423
The bill proposes several key provisions to achieve this goal. Firstly, it aims to increase funding for research into sickle cell disease, with a focus on developing new treatments and improving existing ones. This would help to advance our understanding of the disease and ultimately improve outcomes for patients.
Additionally, the bill seeks to expand access to comprehensive care for individuals with sickle cell disease, including preventive services, pain management, and mental health support. This would help to address the complex needs of patients with this condition and improve their overall quality of life. Furthermore, the bill includes provisions to improve education and awareness of sickle cell disease among healthcare providers and the general public. This would help to ensure that individuals with the disease receive timely and appropriate care, and that they are able to advocate for themselves effectively. Overall, the Sickle Cell Care Expansion Act of 2023 represents a significant step towards improving care and treatment for individuals with sickle cell disease. By increasing funding for research, expanding access to comprehensive care, and improving education and awareness, this bill has the potential to make a real difference in the lives of those affected by this challenging condition.
Congressional Summary of S 1423
Sickle Cell Care Expansion Act of 2023
This bill establishes programs to increase treatment and other services for populations with sickle cell disease. Sickle cell disease is an inherited blood disorder that can lead to pain, anemia, infections, and stroke.
Specifically, the Department of Health and Human Services (HHS) must award grants to federally qualified health centers, community-based organizations, or other nonprofits that treat or otherwise support populations with sickle cell disease for education and advocacy programs concerning the disease. HHS must also award grants to nonprofits, including hospitals or institutions of higher education, that provide comprehensive care to populations with sickle cell disease for programs to support the transition from pediatric to adult care for patients with the disease.
Additionally, the Health Resources and Services Administration must establish a program to provide scholarships or student loan repayment awards to individuals who commit to engage in clinical practice or research related to sickle cell disease for a period of obligated service as physicians.


